D. Solomon

Patient Preferences for First-Line Oral Treatment for Mild-to-Moderate Ulcerative Colitis

P. Hodgkins, S. Dewilde, A. Lloyd, 2012, The Patient - Patient-Centered Outcomes Research.

Twelve-Month Persistency with Oral 5-Aminosalicylic Acid Therapy for Ulcerative Colitis: Results from a Large Pharmacy Prescriptions Database

M. Sumner, S. Kane, D. Solomon, 2011, Digestive Diseases and Sciences.

Adherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis: impact on all-cause healthcare costs: P-0087.

P. Hodgkins, K. Davis, L. Yen, 2009 .

Factors affecting satisfaction with treatment in European women with chronic constipation: An internet survey

A. Bredenoord, E. Rey, J. Sabate, 2013, United European gastroenterology journal.

Strategies in maintenance for patients receiving long‐term therapy (SIMPLE): A study of MMX mesalamine for the long‐term maintenance of quiescent ulcerative colitis*

M. Safdi, K. Barrett, S. Kane, 2012, Inflammatory bowel diseases.

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial

D. Rubin, G. D'Haens, D. Dobru, 2016, Journal of Crohn's & colitis.

Impact of MMX® Mesalamine on Improvement and Maintenance of Health-Related Quality of Life in Patients with Ulcerative Colitis

A. Yarlas, P. Hodgkins, S. Kane, 2013, Inflammatory bowel diseases.

The impact of MMX mesalazine on disease‐specific health‐related quality of life in ulcerative colitis patients

P. Hodgkins, A. Yarlas, S. Kane, 2012, Alimentary pharmacology & therapeutics.

Diverticular disease in Scotland: 2000–2010

P. Hodgkins, I. Arnott, R. Nicholls, 2015, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.